A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection
Clinical trial NCT04343989 · COMPLETED
Trial details
- NCT number
- NCT04343989
- Sponsor
- NYU Langone Health
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-03-31
- Primary completion
- 2021-02-03
- Enrollment
- 178
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.